医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Leading China-Based CRO Selects Instem’s Provantis Portal for Remote Study Monitoring

2013年07月19日 AM04:25
このエントリーをはてなブックマークに追加


 

CONSHOHOCKEN, Pa.

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that WuXi AppTec (WuXi), a leading supplier of R&D services to the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has purchased the Provantis Portal™ Remote Study Monitoring solution.

In 2009, WuXi selected Instem’s integrated Provantis preclinical solution suite to automate study processes at their newly constructed 314,000 square-feet toxicology facility in Suzhou. The Provantis Portal, launched in 2012, now allows WuXi’s toxicology clients to log into a secure Web site using any standard browser to view data from their on-going studies on-demand. This makes it easy for clients, particularly international organizations, to monitor their studies remotely while being able to more effectively communicate internally and with WuXi.

“WuXi’s mission is to create a broad, integrated platform of R&D services that will allow anyone and any company to develop new medicines efficiently and cost effectively,” said Stephen Mason, Vice President of Operations for Preclinical Services at WuXi. “The speed and quality of communications made possible by the Provantis Portal supports our commitment to better serve our customers globally through high-quality services.”

Neil Donaldson, Vice President of Asian and European Operations at Instem, commented, “We are delighted that WuXi continues to take advantage of solutions from within our Study Workflow and Automation suite, and I’m encouraged to hear that their use of the Provantis Portal is bringing immediate value to them and their clients. It is also fantastic to see WuXi expand the number of users and modules of Provantis as they increase capacity at their Suzhou facility.”

As the first western toxicology/pathology software supplier to enter the Chinese market, Instem officially deployed its first China-based system in one of the largest and most advanced vivariums during 2006. Acknowledging analyst projections that the People’s Republic of China (PRC) is on pace to becoming the second largest pharmaceutical market in the world, Instem established a full-service office in Shanghai, recruited local staff and has localized the Provantis product suite into Mandarin Chinese. Instem is supporting international organizations and domestic laboratories exclusively serving the PRC using on-site systems as well as their SaaS delivery model from a professionally managed data center based in Shanghai.

Instem will be demonstrating its Provantis preclinical software suite and the Provantis Portal Remote Study Monitoring Solution at the 3rd China Annual Meeting of Drug Toxicology, Suzhou, China, July 16-19th.

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports its clients through full-service offices in the United States, United Kingdom and China, with additional locations in India and a full-service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

http://www.linkedin.com/company/instem/

https://www.facebook.com/Instem.software

https://twitter.com/Instemsoftware

Meeting clients at the intersection of investment & return™.

CONTACT

Instem
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600
julie.jones@instem.com
or
Gary
Mitchell (US HQ)
Tel: 610-941-0990
gary.mitchell@instem.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作